This CPB is revised to state that emicizumab-kxwh (Hemlibra) is considered medically necessary for routine prophylaxis to prevent or reduce the frequency of bleeding episodes when the member has a documented diagnosis of hemophilia A and the presence of factor VIII inhibitors. This CPB is revised to state that recombinant glycoPEGylated factor IX (Rebinyn) is considered medically necessary for the treatment of adults and children with hemophilia B (FIX activity ≤ 2 IU/dL) who require on-demand treatment and control of bleeding episodes and perioperative management of bleeding.